Category Archives: 2011

Opting to Track Early Prostate Cancer.

A December 20th article by Associated Press medical writer Lauran Neergaard illustrated the difference between “watchful waiting” and “active surveillance” for men diagnosed with early-stage prostate cancer. Most of the 240,000 cases of prostate cancer diagnosed annually in the United more »

Posted in 2011 | Comments Off on Opting to Track Early Prostate Cancer.

November News Items: 1) Watchful-Waiting; 2) New drug TAK-700; 3) Use of Cryotherapy After Failure of Radiation or Brachytherapy.

1) The November 16th, 2011 issue of the Newsletter from Zero-The Project to End Prostate Cancer, published an interesting article from the New York Times entitled “A  Watch-and-Wait Prostate Cancer Treatment.”  The article focused on the PSA screening and subsequent more »

Posted in 2011 | Comments Off on November News Items: 1) Watchful-Waiting; 2) New drug TAK-700; 3) Use of Cryotherapy After Failure of Radiation or Brachytherapy.

MDV3100 Extends Life in Men Whose Prostate Cancer Had Failed Hormonal- and Chemotherapies.

Positive Phase 3 clinical trial results for the drug MDV3100 in men whose prostate cancers had progressed after failing hormonal therapy and chemotherapy have recently been reported in a special edition of the Prostate Cancer Foundation Newsletter, November 7th, 2011 more »

Posted in 2011 | Comments Off on MDV3100 Extends Life in Men Whose Prostate Cancer Had Failed Hormonal- and Chemotherapies.

God Sees the Whole Picture Exceedingly and Abundantly; We Don’t.

I often consider my prostate cancer as “my problem.” I am focused on being maintained in a symptom-free condition for as long as possible, or potential treatments as needed and finally focused on not dying of the disease. But God more »

Posted in 2011 | Comments Off on God Sees the Whole Picture Exceedingly and Abundantly; We Don’t.

FDA Grants Fast Track Designation to Radium-223 Chloride (Alpharadin) for the Treatment of Hormone Refractory Prostate Cancer That Has Spread to the Bone.

At the annual American Society of Clinical Oncology (ASCO) meeting in Chicago in June 2011, the Prostate Cancer Foundation September 30th newsletter reported on promising Phase III clinical trial results for radium-223 chloride (alpharadin), an agent specifically being developed for cancer patients more »

Posted in 2011 | Comments Off on FDA Grants Fast Track Designation to Radium-223 Chloride (Alpharadin) for the Treatment of Hormone Refractory Prostate Cancer That Has Spread to the Bone.

b) Earliest Known Cases of Prostate Cancer.

In an article published in the International Journal of Paleopathology, a research team in Portugal has recently diagnosed the oldest known case of prostate cancer in ancient Egypt and the second oldest documented case in the world. The earliest diagnosis more »

Posted in 2011 | Comments Off on b) Earliest Known Cases of Prostate Cancer.

Update on Government Panel Recommendation to Discontinue PSA Screening.

As discussed in this website blog posted on October 15th, a government medical panel, the United States Preventive Services Task Force, recently recommended that routine PSA testing in healthy men under the age of 75 be discontinued unless they have more »

Posted in 2011 | Comments Off on Update on Government Panel Recommendation to Discontinue PSA Screening.

URGENT ACTION NEEDED! Government Proposes Elimination of Prostate Cancer Testing. Does PSA Screening for Prostate Cancer Save Lives?

The United States Preventive Services Task Force (USPSTF), an independent panel appointed by the Federal cabinet-level Department of Health and Human Services (DHHS), is preparing a recommendation which would eliminate prostate cancer testing (PSA) for all men. The rationale cited more »

Posted in 2011 | Comments Off on URGENT ACTION NEEDED! Government Proposes Elimination of Prostate Cancer Testing. Does PSA Screening for Prostate Cancer Save Lives?

Variations in Five Genes May Identify Lethal Varieties of Prostate Cancer.

For years, the general practice used in the initial screening for prostate cancer is a blood test for prostate-specific antigen (PSA) in conjunction with a digital rectal examination. These tests are then used to determine whether or not to subject more »

Posted in 2011 | Comments Off on Variations in Five Genes May Identify Lethal Varieties of Prostate Cancer.

Prostate Cancer Stem Cells: A New Target for Treating Hormone-Refractory Cancer.

It has been known for over 60 years that in general, prostate cancer cells respond to androgen deprivation (hormonal) therapy. At some point however, the prostate cells no longer respond (they become hormone-refractory) and levels of prostate-specific antigen (PSA) begin more »

Posted in 2011 | Comments Off on Prostate Cancer Stem Cells: A New Target for Treating Hormone-Refractory Cancer.